MedTrace Logo

Acute Effects of Cannabigerol

NCT05257044 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2024-04-25

No results posted yet for this study

Summary

The purpose of this study is to examine the effects of hemp-derived cannabigerol (CBG) on anxiety, stress, mood, and cognition. Further, the severity of various side effects of CBG (sleepiness, dry mouth, dry eyes, increased appetite) will be assessed. As such, the study is focused on better understanding some of the potentially beneficial and detrimental effects of CBG on humans.

Conditions

  • Focus: To Examine Acute Effects of CBG on Anxiety, Stress, and Cognition

Interventions

DRUG

Cannabigerol

Participants will ingest CBG and placebo in a double-blind randomized cross-over design

OTHER

Placebo

Placebo

Sponsors & Collaborators

  • Washington State University

    lead OTHER

Principal Investigators

  • Carrie Cuttler, PhD · Washington State University

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-03-24
Primary Completion
2023-11-28
Completion
2023-11-28

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05257044 on ClinicalTrials.gov